NephrosNEPH
13F holders, Q3 2024 (September 30)At the end of Q3 2024, 17 institutions reported holding Nephros Inc. (NEPH) in their 13F filings, down 2 from Q2 2024. 0 opened new positions and 2 sold out. The largest holders were Wexford Capital LP ($6.2M), Vanguard Group Inc. ($345K) and Bard Associates Inc. ($295K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Nephros Inc.
- CUSIP
- 640671400
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $55K |
All 13F filers, Q2 2024 → Q3 2024: 21,033 shares bought and 68,630 shares sold, net −47,597 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Wexford Capital LP | 1.47% | No change | 3,600,552 | $6.2M |
| Vanguard Group Inc. | 0.00% | Add +4.1% | 201,994 | $345K |
| Bard Associates Inc. | 0.10% | Reduce -1.8% | 172,371 | $295K |
| Geode Capital Management, LLC | 0.00% | Add +9.2% | 85,249 | $146K |
| HighTower Advisors, LLC | 0.00% | No change | 57,210 | $98K |
| Elkhorn Partners Limited Partnership | 0.04% | Add +1.2% | 36,441 | $62K |
| Blair William & Co. | 0.00% | No change | 36,249 | $62K |
| Renaissance Technologies | 0.00% | Reduce -40.4% | 24,444 | $42K |
| Citadel Advisors | 0.00% | Add +45.5% | 17,236 | $29K |
| State Street Corp. | 0.00% | No change | 15,698 | $27K |
| Dimensional Fund Advisors LP | 0.00% | Reduce -15.6% | 14,875 | $25K |
| Mesirow Financial Investment Management, Inc. | 0.00% | No change | 13,800 | $24K |
| Morgan Stanley | 0.00% | No change | 5,423 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -24.0% | 2,791 | $5K |
| JPMorgan Chase & Co. | 0.00% | Reduce -0.5% | 221 | $378 |
| UBS Group AG | 0.00% | Reduce -99.4% | 121 | $207 |
| Bank of America Corp. | 0.00% | Add +26.3% | 96 | $164 |
"% of holder's portfolio" is NEPH's weight in each manager's 13F, not the share of Nephros Inc. the manager owns.